Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
CRM -0.1NOA.TO 0.01U.UN.TO -0.08BLX -0.19ELF.TO -0.23RY.TO 1.72PEY.TO -0.29CP.TO -3.89
Daily Stock Opinions and Ratings
Stockchase Opinions

Hugh Cleland, CFAResverlogix Corp.RVX.TOCOMMENTDec 27, 2007

Have some compounds that are expected to boost HDL levels significantly. He usually has trouble with pure biotechs, which this one is. They consume vast amounts of cash. Prefers Neptune (NTB-X).
Hugh Cleland, CFAHugh Cleland, CFA
No
Unlock Rating
$15.42

Stock price when the opinion was issued

$0.10

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist
Track your Stocks in your Watch List

You might be interested:

COMMENT

Resverlogix Corp.(RVX.TO)

Nov 16, 2009
(Market Call Minute.)Reversing of bad cholesterol in clinical studies. A little early for him but has potential. Speculative.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$2.58

Stock price when the opinion was issued

$0.10

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Resverlogix Corp.(RVX.TO)

Aug 06, 2009
Only process that can reverse a cholesterol situation. A lot of big pharmas are looking at the name. Looks pretty attractive at this level. This is at phase 2 and he prefers buying after phase 3.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$2.79

Stock price when the opinion was issued

$0.10

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Resverlogix Corp.(RVX.TO)

Mar 26, 2007
Strong management. Have an interesting approach to HDL. Currently pre-clinical, so doesn't know if it works in humans or is safe.
Photo of Hugh Cleland, CFAHugh Cleland, CFA
No
Unlock Rating
$16.90

Stock price when the opinion was issued

$0.10

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Resverlogix Corp.(RVX.TO)

Jan 24, 2007
Treatment of Cardiovascular diseases. They’re on to a new way of looking at HDL treatment. Still pre-clinical. Prefers biotech that is at least in phase 2 trials. Too expensive.
Photo of Hugh Cleland, CFAHugh Cleland, CFA
No
Unlock Rating
$19.11

Stock price when the opinion was issued

$0.10

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

SAN -0.05$13.33
MS 4.13$224.96
GS 8.47$1099.14
COF 2.53$203.4
INGR -1.97$98.84

Today's Top Picks

CRM -0.1$154.92
NOA.TO 0.01$18.92
U.UN.TO -0.08$26.76
BLX -0.19$59.05
ELF.TO -0.23$16.75

Popular Articles

Latest Sell Signals

SYK -9.44$301.14
FICO -0.84$1126
BBD.B.TO -6.39$303.18
MTL.TO -1.12$21.34
BN.TO -0.73$63.22

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

John Zechner

John Zechner

J. Zechner & Assoc

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica